MedTrace Logo

The Influence of Intranasal Oxytocin on Communication

NCT02415920 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-04-17

No results posted yet for this study

Summary

This study investigates whether oxytocin, a neuropeptide known for its role in social bonding, influences the outcomes of persuasive communications and several primary evolutionary goals. Participants will be given either oxytocin or placebo on their first visit and then they will receive the other spray during their second visit. At each visit, participants will engage in several psychosocial tasks to assess the role of oxytocin on receptiveness to opposing opinions, navigating the spatial environment, mating and parenting goals. Participants' attitudes and behaviours will be compared across the different conditions.

Conditions

  • Healthy

Interventions

DRUG

Oxytocin

Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.

DRUG

Placebo

Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.

Sponsors & Collaborators

  • Natural Sciences and Engineering Research Council, Canada

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Frances Chen, PhD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-06
Primary Completion
2018-12-12
Completion
2018-12-12

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02415920 on ClinicalTrials.gov